FeMike, I agree pfs was confounded due to pseudoprogressors but on slide 11 from the NYAS 5/10 presentation it shows that pfs was basically the same for treatment and placebo with a small advantage to the placebo group, so imo it does appear to be a fail. OS and the long survival tail is the success. Will be interesting to see the statistics on the placebos that did not crossover to treatment- someday I hope. Also an update on the information arm would be interesting